-
Ebb & Flow Banker tracks Noel Brown will join RBC Capital Markets as a managing director in the firm's healthcare investment banking group responsible for life sciences, effective Aug. 1. He is a managing director …
Published on 5/20/2013
-
Elan is betting its shareholders will like the return from investing $1 billion for a slice of Theravance's royalties, but Theravance shareholders signaled they liked the cash better.
Published on 5/20/2013
-
Liquidity preference The flow of cash In a deal with many moving parts, Elan Corp. plc (NYSE:ELN) agreed last week to pay $1 billion for a 21% share of future royalties on sales of four respiratory products that …
Published on 5/20/2013
-
Merck Serono's earnest money MS Ventures portfolio MS Ventures is managing investments in a portfolio of 12 companies working in areas relevant to Merck Serono S.A.'s focus in cancer, autoimmune, neurodegenerative …
Published on 5/20/2013
-
PeptiDreams of an IPO EPS watch At least seven biotechs and pharmas reported earnings last week. Astellas Pharma Inc. (Tokyo:4503) tacked on more than $700 million to its market cap after reporting EPS and revenues …
Published on 5/20/2013
-
PeptiDreams of an IPO Money Raised in 2013 Last week, the biotech industry raised $1,108 million, bringing to $9.6 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9…
Published on 5/20/2013
-
Figure: Money Raised in 2013 Table: EPS watch A year after starting the IPO process, PeptiDream Inc. hopes it will still be able to benefit from …
Published on 5/20/2013
-
Ebb & Flow Regulatory milestones Algeta ASA (OSE:ALGETA) gained NOK16 to NOK220 last week after FDA approved an NDA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant …
Published on 5/20/2013
-
With fresh EUR 60 million from its pharma parent, MS Ventures aims to take an active role in its portfolio companies and expand from its early stage focus into selected later-stage opportunities.
Published on 5/20/2013
-
Ebb & Flow Striking similarity Vivus Inc. (NASDAQ:VVUS) has steadfastly opposed the director slate put forward by First Manhattan, but some of the biotech's recent board additions bear a striking similarity with …
Published on 5/20/2013
-
Ebb & Flow A little less lumpy Atlas Venture recruited Amgen Inc. and Novartis AG as more than just new LPs in its ninth fund - the VC hopes closer ties with the companies will deliver useful feedback on potential …
Published on 5/20/2013
-
Ebb & Flow Banker tracks Michael Muntner and Charlie Newton were promoted to co-heads of Americas healthcare in Credit Suisse's investment banking department. The two will remain managing directors on the Americas …
Published on 5/13/2013
-
Watch me launch EPS watch At least 17 biotechs and pharmas reported earnings last week. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) lost $2.8 billion in market value on the week after lowering its guidance for the …
Published on 5/13/2013
-
Ebb & Flow Watch me launch Table: Earnings on deck Figure: Money Raised in 2013 Table: EPS watch Isis Pharmaceuticals Inc. (NASDAQ:ISIS) didn't wait for investors to learn launch details of hypercholesterolemia …
Published on 5/13/2013
-
Ebb & Flow Walk in the park Park Vale Capital will hit the road this week to raise money for a new fund that will primarily invest in companies with Orphan programs in late Phase II or Phase III testing. The U.K. …
Published on 5/13/2013
-
Ebb & Flow Regulatory milestones ALK-Abello A/S (CSE:ALK-B) was down DKK3 to DKK416 last week after FDA accepted for review a BLA from partner Merck & Co. Inc. (NYSE:MRK) for Ragweed Allergy Immunotherapy Tablet (…
Published on 5/13/2013
-
While several VCs have stepped back from early stage diagnostics, other firms think the evolution of underlying technologies and need to control healthcare costs make it an ideal time to invest.
Published on 5/13/2013
-
Ebb & Flow Bile be gone Lumena Pharmaceuticals Inc. is looking to advance its lead compound LUM001 through three Phase II cholestatic liver disease trials with funds from its $23 million series A. President and CEO…
Published on 5/13/2013
-
Atlas Venture will stick to its seedlings strategy with its new ninth fund, but will not deploy any of the new money into young diagnostic companies.
Published on 5/6/2013
-
Ebb & Flow Banker tracks Bill Suddath rejoined Baird as a managing director on the firm's healthcare investment banking team, focusing on healthcare IT and services. Suddath led the healthcare IT and specialty …
Published on 5/6/2013
-
Ebb & Flow Money Raised in 2013 Last week, the biotech industry raised $642 million, bringing to $8 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion in …
Published on 5/6/2013
-
Ebb & Flow Earnings on deck At least 12 biotechs and pharmas are slated to report earnings this week. Vivus Inc. (NASDAQ:VVUS) will report the second full quarter of sales of obesity drug Qsymia phentermine/…
Published on 5/6/2013
-
Ebb & Flow EPS watch At least 30 biotechs and pharmas reported earnings last week. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) was up 23% for the week, adding $4.8 billion to its market cap. The company beat …
Published on 5/6/2013
-
Ebb & Flow Perpetual acceleration Figure: Money Raised in 2013 Table: Earnings on deck Table: EPS watch Harvard University hopes that a $50 million gift will bring enough early stage projects to a partnering …
Published on 5/6/2013
-
After topping up its coffers, the antibody platform play has the cash and investor base to build out its pipeline and take at least one product to market itself.
Published on 5/6/2013